Scientific Research Publishing

Guillain-Barré Syndrome Presenting as Pseudo-Cerebellar Syndrome: A Case Report from a Resource-Limited Setting in Sub-Saharan Africa ()

Guillain-Barré Syndrome Presenting as Pseudo-Cerebellar Syndrome: A Case Report from a Resource-Limited Setting in Sub-Saharan Africa Guillain-Barré Syndrome (GBS) is the most frequent cause of acute ...

Simple Tricks To Help Seniors Drink More Water

Helping a senior stay hydrated isn't about forced consumption; it's about making the healthy choice the easiest choice. By infusing water with flavor, serving "watery" foods, and setting a gentle ...
Kauppalehti

Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease

Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...
TMCnet

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ®  (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in ...

Idorsia Pharmaceuticals Ltd: Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease

Allschwil, Switzerland - February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker ...